CCL2 and ulcerative colitis: Messal et al., using an animal model of ulcerative colitis, have demonstrated the anti-inflammatory effects of orexin-A via decreasing the expression of pro-inflammatory cytokines, amongst them MCP-1 in immune cells, an effect mediated by OX1R [9].